PSMA may be a noninvasive biomarker for predicting treatment response in metastatic clear cell renal cell carcinoma (RCC).
Jacob E. Berchuck, MD, highlights challenges in adopting liquid biopsy for PSMA expression and its potential to revolutionize precision medicine in prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback